Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share price took a hit due to inconclusive NIPU top-line data. We judge INITIUM top-line data in H1 2024e and more detailed NIPU data in Q4 2023e could provide critical catalysts for the share. We make minor changes in our valuation model.